Evidence map›Paper›PMID 32962626›Full record

ArticleBMC genomics2020

Multi-scale supervised clustering-based feature selection for tumor classification and identification of biomarkers and targets on genomic data.

Da Xu, Jialin Zhang, Hanxiao Xu, Yusen Zhang, Wei Chen, Rui Gao, Matthias Dehmer

Abstract read
In one paragraph

Article in BMC genomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Da XuSchool of Mathematics and Statistics, Shandong University, Weihai, 264209, China.
Jialin ZhangSchool of Mathematics and Statistics, Shandong University, Weihai, 264209, China.
Hanxiao XuSchool of Mathematics and Statistics, Shandong University, Weihai, 264209, China.
Yusen ZhangSchool of Mathematics and Statistics, Shandong University, Weihai, 264209, China. zhangys@sdu.edu.cn.ORCID http://orcid.org/0000-0003-3842-1153
Wei ChenSchool of Mathematics and Statistics, Shandong University, Weihai, 264209, China.
Rui GaoSchool of Control Science and Engineering, Shandong University, Jinan, 250061, China.
Matthias DehmerInstitute for Intelligent Production, Faculty for Management, University of Applied Sciences Upper Austria, Steyr Campus, Steyr, Austria.

Funding

Austrian Science Funds (FWF) P30031National Natural Science Foundation of China 61533011National Natural Science Foundation of China 61877064National Natural Science Foundation of China U1806202
6 · The paper itself

Abstract

backgroundThe small number of samples and the curse of dimensionality hamper the better application of deep learning techniques for disease classification. Additionally, the performance of clustering-based feature selection algorithms is still far from being satisfactory due to their limitation in using unsupervised learning methods. To enhance interpretability and overcome this problem, we developed a novel feature selection algorithm. In the meantime, complex genomic data brought great challenges for the identification of biomarkers and therapeutic targets. The current some feature selection methods have the problem of low sensitivity and specificity in this field.

resultsIn this article, we designed a multi-scale clustering-based feature selection algorithm named MCBFS which simultaneously performs feature selection and model learning for genomic data analysis. The experimental results demonstrated that MCBFS is robust and effective by comparing it with seven benchmark and six state-of-the-art supervised methods on eight data sets. The visualization results and the statistical test showed that MCBFS can capture the informative genes and improve the interpretability and visualization of tumor gene expression and single-cell sequencing data. Additionally, we developed a general framework named McbfsNW using gene expression data and protein interaction data to identify robust biomarkers and therapeutic targets for diagnosis and therapy of diseases. The framework incorporates the MCBFS algorithm, network recognition ensemble algorithm and feature selection wrapper. McbfsNW has been applied to the lung adenocarcinoma (LUAD) data sets. The preliminary results demonstrated that higher prediction results can be attained by identified biomarkers on the independent LUAD data set, and we also structured a drug-target network which may be good for LUAD therapy.

conclusionsThe proposed novel feature selection method is robust and effective for gene selection, classification, and visualization. The framework McbfsNW is practical and helpful for the identification of biomarkers and targets on genomic data. It is believed that the same methods and principles are extensible and applicable to other different kinds of data sets.

Indexed as

Supervised Machine LearningAdenocarcinoma of LungBiomarkers, TumorCluster AnalysisGenomicsHumansLung NeoplasmsSoftwareBiomarkers, TumorBiomarkerClassificationClusteringFeature selectionMachine learningTherapeutic target

Identifiers

PMID32962626
PMCPMC7510277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.